Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Genitourinary 3Head & Neck 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Low Anterior Resection Syndrome 1Gastroparesis 1Esophageal Neoplasms 1Esophageal Motility Disorders 1Esophageal Diseases 1Esophageal Achalasia 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 324Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Botulinum Toxins, Type A × Gastrointestinal × Clear all
NCT06721520 2026-02-25

EMPTY

The Cleveland Clinic

Phase 2/3 Recruiting
170 enrolled
Gastrointestinal

Esophageal Achalasia, Esophageal Diseases, Esophageal Motility Disorders, Gastroparesis

NCT04965311 2025-05-13

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

OHSU Knight Cancer Institute

Phase 2 Terminated
4 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02965976 2023-02-16

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Roswell Park Cancer Institute

Phase 2 Completed
33 enrolled 17 charts
Gastrointestinal

Esophageal Neoplasms

NCT01822210 2018-03-09

Botulinum Toxin for Stomach Cancer Treatment

St. Olavs Hospital

Phase 2 Completed
7 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01589471 2018-02-12

The Value of Botox-A for Management of Low Anterior Resection Syndrome

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 2 Completed
23 enrolled
Gastrointestinal

Low Anterior Resection Syndrome, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡